Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum

References

• Grann A, Feng C, Wong D, Saltz L, Paty PP, Guillem JG, Cohen AM, Minsky BD. Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2001; 49: 987–995
   PubMed Web of Science ®Google Scholar
• Luna-Perez P, Rodriguez-Ramirez S, Hernandez-Pacheco F, Gutierrez De La Barrera M, Fernandez R, Labastida S. Anal sphincter preservation in locally advanced low rectal adenocarcinoma after preoperative chemoradiation therapy and coloanal anastomosis. J Surg Oncol 2003; 82: 3–9
   PubMedGoogle Scholar
• Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum 2004; 47: 1798–1807
   PubMed Web of Science ®Google Scholar
• Capirci C, Valentini V, Cionini L, De Paoli A, Rödel C, Glynne-Jones R, Coco C, Romano M, Mantello G, Palazzi S, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: Long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72: 99–107
   PubMed Web of Science ®Google Scholar
• Theodoropulos G, Padmanabhan A, Kerner BA, Taylor CW, Aguila PS, Khaduja KS. T-level downstaging and complete pathological response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002; 45: 895–899
   PubMedGoogle Scholar
• Mohiuddin M, Hayne M, Regine WF, Hanna N, Hagihara PF, McGrath P, Marks GM. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent cancers. Int J Radiat Oncol Biol Phys 2000; 48: 1075–1080
   PubMed Web of Science ®Google Scholar
• Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688–8696
   PubMed Web of Science ®Google Scholar
• Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G, Urso ED, Del Bianco P, Sotti G, Lise M, et al. A phase I - II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 2005; 16: 1140–1146
   PubMed Web of Science ®Google Scholar
• Gérard JP, Chapet O, Nemoz C, Romestaing P, Mornex F, Coquard R, Barbet N, Atlan D, Adeleine P, Freyer G. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: The Lyon R0-04 phase II trial. J Clin Oncol 2003; 21: 1119–1124
   PubMed Web of Science ®Google Scholar
• Carraro S, Roca EL, Cartelli C, Rafailovici L, Castillo Odena S, Wasserman E, Gualdrini U, Huertas E, Barugel M, Ballarino G, et al. Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3 - T4 unresectable rectal cancer: A phase II IATTGI study. Int J Radiat Oncol Biol Phys 2002; 54: 397–402
   PubMed Web of Science ®Google Scholar
• Gambacorta MA, Valentini V, Coco C, Morganti AG, Smaniotto D, Miccichè F, Mantini G, Barbaro B, Garcia-Vargas JE, Magistrelli P, et al. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies. Int J Radiat Oncol Biol Phys 2004; 60: 139–148
   PubMed Web of Science ®Google Scholar
• Klautke G, Feyerherd P, Ludwig K, Prall F, Foitzik T, Fietkau R. Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer 2005; 92: 1215–1220
   PubMed Web of Science ®Google Scholar
• Rödel C, Sauer R. Integration of novel agents into combined-modality treatment for rectal cancer patients. Strahlenther Onkol 2007; 183: 227–235
   PubMedGoogle Scholar
• Dunst J, Reese T, Sutter T, Zühlke H, Hinke A, Kölling-Schlebusch K, Frings S. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002; 20: 3983–3991
   PubMed Web of Science ®Google Scholar
• Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098–3104
   PubMed Web of Science ®Google Scholar
• Rödel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Fürst A, Schwella N, Bieker M, Hellmich G, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007; 25: 110–117
   PubMed Web of Science ®Google Scholar
• Carlomagno C, Farella A, Bucci L, D'Armiento FP, Pesce G, Pepe S, Cannella L, Pacelli R, De Stefano A, Solla R, et al. Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: A phase II study. Ann Oncol 2009; 20: 906–912
   PubMedGoogle Scholar
• Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Ströbel P, Erben P, Woernle C, Dinter D, Kähler G, et al. Cetuximab in Combination with Capecitabine, Irinotecan, and Radiotherapy for Patients with Locally Advanced Rectal Cancer: Results of a Phase II MARGIT Trial. Int J Radiat Oncol Biol Phys 2009; 74: 1487–1493
   PubMed Web of Science ®Google Scholar
• Bertolini F, Chiara S, Bengala C, Antognoni P, Dealis C, Zironi S, Malavasi N, Scolaro T, Depenni R, Jovic G, et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: A phase II study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2009; 73: 466–472
   PubMed Web of Science ®Google Scholar
• Rödel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, Hermann RM, Lordick F, Hinke A, Hohenberger W, et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 1081–1086
   PubMed Web of Science ®Google Scholar
• Valentini V, De Paoli A, Gambacorta MA, Mantini G, Ratto C, Vecchio FM, Barbaro B, Innocente R, Rossi C, Boz G, et al. Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: A phase I and II Trial (1839IL/0092). Int J Radiat Oncol Biol Phys 2008; 72: 644–649
   PubMed Web of Science ®Google Scholar
• Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, Ludwig KA, Mantyh CR, Ashton J, et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys 2007; 68: 472–478
   PubMed Web of Science ®Google Scholar
• Willett CG, Duda DG, Tomaso di, Boucher E, Czito Y, Vujaskovic BG, Vlahovic Z, Bendell G, Cohen J, Hurwitz KS, et al. Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol 2007; 4: 316–321
   PubMedGoogle Scholar
• Urso E, Serpentini S, Pucciarelli S, De Salvo GL, Friso ML, Fabris G, Lonardi S, Ferraro B, Bruttocao A, Aschele C, et al. Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer. Eur J Surg Oncol 2006; 32: 1201–1208
   PubMedGoogle Scholar
• Schulze T, Wust P, Gellermann J, Hildebrandt B, Riess H, Felix R, Rau B. Influence of neoadjuvant radiochemotherapy combined with hyperthermia on the quality of life in rectum cancer patients. Int J Hyperthermia 2006; 22: 301–318
   PubMed Web of Science ®Google Scholar
• Fietkau R, Barten M, Klautke G, Klar E, Ludwig K, Thomas H, Brinckmann W, Friedrich A, Prall F, Hartung G, Küchenmeister U, Kundt G. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis Colon Rectum. 2006; 49: 1284–1292
   PubMedGoogle Scholar
• Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, Radosevic-Jelic L, Piérart M, Calais G, European Organisation for Research and Treatment of Cancer Radiation Oncology Group. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: Does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25: 4379–4386
   PubMed Web of Science ®Google Scholar
• Fietkau R, Klautke G. Adjuvant chemotherapy following neoadjuvant therapy of rectal cancer: The type of neoadjuvant therapy (chemoradiotherapy or radiotherapy) may be important for selection of patients. J Clin Oncol. 2008; 26: 507–508
   PubMed Web of Science ®Google Scholar
• Rau B, Wust P, Hohenberger P, Löffel J, Hünerbein M, Below C, Gellermann J, Speidel A, Vogl T, Riess H, et al. Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer: A phase II clinical trial. Ann Surg 1998; 227: 380–389
   PubMed Web of Science ®Google Scholar
• Wust P, Rau B, Gellerman J, Pegios W, Löffel J, Riess H, Felix R, Schlag PM. Radiochemotherapy and hyperthermia in the treatment of rectal cancer. Recent Results Cancer Res 1998; 146: 175–191
   PubMedGoogle Scholar
• Anscher MS, Lee C, Hurwitz H, Tyler D, Prosnitz LR, Jowell P, Rosner G, Samulski T, Dewhirst MW. A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer. Int J Radiat Oncol Biol Phys 2000; 47: 719–724
   PubMed Web of Science ®Google Scholar
• Fritzmann J, Hünerbein M, Slisow W, Gellermann J, Wust P, Rau B. Influence of preoperative (hyperthermic) radiochemotherapy on manometric anal sphincter function in locally advanced rectal cancer. Strahlenther Onkol 2004; 180: 281–288
   PubMedGoogle Scholar
• Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am 2003; 12: 755–769
   PubMedGoogle Scholar
• Liang H, Zhan HJ, Wang BG, Pan Y, Hao XS. Change in expression of apoptosis genes after hyperthermia, chemotherapy and radiotherapy in human colon cancer transplanted into nude mice. World J Gastroenterol 2007; 13: 4365–4371
   PubMed Web of Science ®Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31: 1341–1346
   PubMed Web of Science ®Google Scholar
• Knight CD, Griffen FD. An improved technique for low anterior resection of the rectum using the EEA stapler. Surgery 1980; 88: 710–714
   PubMed Web of Science ®Google Scholar
• Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731–1740
   PubMed Web of Science ®Google Scholar
• Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol 2006; 24: 4620–4625
   PubMed Web of Science ®Google Scholar
• Pucciarelli S, Gagliardi G, Maretto I, Lonardi S, Friso ML, Urso E, Toppan P, Nitti D. Long-term oncologic results and complications after preoperative chemoradiotherapy for rectal cancer: A single-institution experience after a median follow-up of 95 months. Ann Surg Oncol 2009; 16: 893–899
   PubMedGoogle Scholar
• Klautke G, Fietkau R. Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: A review. Int J Colorectal Dis. 2007; 22: 457–465
   PubMed Web of Science ®Google Scholar
• Gosens MJ, Klaassen RA, Tan-Go I, Rutten HJ, Martijn H, van den Brule AJ, Nieuwenhuijzen GA, van Krieken JH, Nagtegaal ID. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res. 2007; 13: 6617–6623
   PubMed Web of Science ®Google Scholar
• Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev Jan 21, 2009, 1: CD006041
   Google Scholar
• Kido Y, Kuwano H, Maehara Y, Mori M, Matsuoka H, Sugimachi K. Increased cytotoxicity of low-dose, long-duration exposure to 5-fluorouracil of V-79 cells with hyperthermia. Cancer Chemother Pharmacol 1991; 28: 251–254
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Sugimachi K, Abe R, Ueo H, Akiyoshi T. Enhancement of cytotoxicity by hyperthermia after a long-term culture with 5-fluorouracil in transformed cells. Anticancer Res 1992; 12: 1621–1625
   PubMed Web of Science ®Google Scholar
• Maeta M, Sawata T, Kaibara N. Effects of hyperthermia on the metabolism of 5-fluorouracil in vitro. Int J Hyperthermia 1993; 9: 105–113
   PubMed Web of Science ®Google Scholar
• van der Zee J, González González D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000; 355: 1119–1125
   PubMed Web of Science ®Google Scholar
• Wust P, Cho CH, Hildebrandt B, Gellermann J. Thermal monitoring: Invasive, minimal-invasive and non-invasive approaches. Int J Hyperthermia. 2006; 22: 255–262
   PubMed Web of Science ®Google Scholar
• Leopold KA, Dewhirst MW, Samulski TV, Dodge RK, George SL, Blivin JL, Prosnitz LR, Oleson JR. Cumulative minutes with T90 greater than Tempindex is predictive of response of superficial malignancies to hyperthermia and radiation. Int J Radiat Oncol Biol Phys 1993; 25: 841–847
   PubMed Web of Science ®Google Scholar
• Tilly W, Gellermann J, Graf R, Hildebrandt B, Weissbach L, Budach V, Felix R, Wust P. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0. Strahlenther Onkol. 2005; 181: 35–41
   PubMed Web of Science ®Google Scholar
• Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114–1123
   PubMed Web of Science ®Google Scholar